PMV Pharmaceuticals (PMVP)
(Delayed Data from NSDQ)
$1.57 USD
-0.01 (-0.63%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $1.56 -0.01 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
PMVP 1.57 -0.01(-0.63%)
Will PMVP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PMVP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PMVP
Here's Why You Should Consider Buying Bioventus (BVS) Stock
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher
PMVP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High?
Other News for PMVP
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
Buy Rating on PMV Pharmaceuticals: Strategic Partnerships and Promising Clinical Pipeline Underpin Positive Outlook
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
PMV Pharmaceuticals, Foundation Medicine announce collaboration